Moxonidine Tablet
Description
MND-0.3
Moxonidine 0.3 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Moxonidine IP — 0.3 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
MND-0.3 contains Moxonidine 0.3 mg, a centrally acting antihypertensive agent formulated for the effective management of essential hypertension and long-term cardiovascular protection. Moxonidine acts by selectively stimulating imidazoline I1 receptors in the brainstem, reducing sympathetic nervous system activity and lowering peripheral vascular resistance, resulting in effective blood pressure control with improved tolerability compared with many traditional centrally acting antihypertensive agents.
Moxonidine is widely prescribed in cardiology and internal medicine for patients with essential hypertension, resistant hypertension, metabolic syndrome, obesity-associated hypertension, diabetes-associated hypertension, and increased sympathetic activity. It helps reduce systolic and diastolic blood pressure, improve insulin sensitivity, decrease sympathetic overactivity, and reduce cardiovascular risk.
MND-0.3 is particularly beneficial for patients with uncontrolled hypertension, metabolic syndrome, obesity, diabetes mellitus, chronic kidney disease, and patients requiring long-term antihypertensive therapy with favorable metabolic effects.
Technical Knowledge of Moxonidine
Moxonidine selectively stimulates central imidazoline I1 receptors located in the rostral ventrolateral medulla of the brainstem. Activation of these receptors suppresses sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, reduced renin secretion, and sustained blood pressure reduction.
Unlike older centrally acting agents, Moxonidine has greater selectivity for imidazoline receptors and less affinity for alpha-2 adrenergic receptors, contributing to a lower incidence of sedation, dry mouth, and other central nervous system adverse effects.
Mechanism of Action
Moxonidine stimulates central imidazoline I1 receptors, suppresses sympathetic nervous system activity, reduces peripheral vascular resistance, decreases heart rate, lowers blood pressure, reduces renin secretion, and improves autonomic cardiovascular regulation.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Reduces sympathetic overactivity
Provides sustained antihypertensive action
May improve insulin sensitivity
Supports cardiovascular protection
Favorable metabolic profile
Suitable for resistant hypertension
Convenient once-daily dosing
Suitable for long-term hypertension management under medical supervision
Clinical Applications
MND-0.3 is commonly prescribed for essential hypertension, resistant hypertension, hypertension with metabolic syndrome, hypertension with obesity, hypertension with diabetes mellitus, hypertension with chronic kidney disease, and long-term cardiovascular risk reduction.
Facts About Moxonidine
Moxonidine is a selective imidazoline receptor agonist with proven efficacy in reducing blood pressure through central sympathetic inhibition. It is particularly valuable in patients with metabolic syndrome, obesity, insulin resistance, and increased sympathetic activity. Clinical studies have demonstrated effective blood pressure reduction with favorable metabolic and autonomic effects.
Key Facts
Selective imidazoline I1 receptor agonist
Moxonidine 0.3 mg for sympathetic blood pressure control
Reduces central sympathetic activity
May improve insulin sensitivity
Favorable metabolic and cardiovascular profile
Evidence-based antihypertensive therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
MND-0.3 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, obesity, metabolic syndrome, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose MND-0.3 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Moxonidine 0.3 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
MND-0.3 from DIABGLYM combines effective blood pressure control, sympathetic modulation, favorable metabolic benefits, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Moxonidine formulation.
